At AHA, A Debate Over Drug-Eluting Stents
If any medical device should confirm the role of clinical trials in influencing adoption, it's drug-eluting stents. But a debate at the American Heart Association meeting made clear that evidence-based medicine wasn't the ony side of the story. Beyond simple resistance to change, real-world issues--concerns over costs and unforeseen future consequences, among the most notable--often argue more strongly to physicians.
You may also be interested in...
Recent safety issues with drug-eluting stents may have opened the door ever so slightly for cardiac surgeons and coronary artery bypass graft (CABG) surgery to stage a small but noticeable comeback in the treatment of coronary artery disease.
Cardiovascular investigators are now asking new questions, including how can treatment be targeted to those most likely to benefit, and when does aggressive treatment become too much? At the 2006 American Heart Association (AHA) meeting, these questions were at the top of everyone's list, and several highly anticipated studies attempted to provide some answers.
A short summary of recent market and product developments in Interventional Cardiology, Spine Surgery, and Aesthetics, including: DES Safety Panel Weighs the Evidence; Percutaneous Lubar Fusion, and New Dermal Fillers.